(MENAFN- Jordan News Agency)
Amman, May 16 (Petra) -- The Jordan Food and Drug Administration (JFDA) and the American Chamber of Commerce in Jordan (AmCham-Jordan), representing the International Research Pharmaceutical Companies Group, inked a memorandum of understanding to improve Jordan's attractiveness to clinical research and enable patients to access innovative treatments.
The memorandum stipulates mutual commitment between the public and private sectors to support and complete their duties and functions from a development perspective of national health care by ensuring access to innovative treatments in Jordan. The memorandum focuses on enhancing the quality and efficiency of medical products to improve patient care and health care through partnership with the authorities to ensure equitable access to treatments.
The memorandum was signed by Director General of the JFDA Nizar Muhaidat, President of the AmCham-Jordan Samer Judeh, and Head of the Department of the International Research Pharmaceutical Companies Group operating in Jordan Moaz Zaghoul.
Muhaidat said that the memorandum includes the implementation of action plans and joint programs to serve the pharmaceutical and research sector in Jordan in the areas of developing the electronic system used in drug registration, conducting an analysis of the scientific research environment within specific criteria and discussing the results of the analysis and recommendations with experts.
Joudeh stated that the memorandum focuses on medical products and their efficiency to improve health care through partnership with local authorities to ensure fair access to treatments, make a quantum leap in innovative medicines and leverage the expertise of the leading international pharmaceutical companies.
For his part, Zaghoul said that the memorandum is an important step to strengthen the partnership between the public and private sectors in line with the vision of modernizing the health sector in the Kingdom as well as strengthening Jordan's position as a regional hub for clinical studies and research.
MENAFN16052023000117011021ID1106256011
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.